Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis
Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that therapeutic levels are achieved within the perito...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-09-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971219302930 |
| _version_ | 1811282942022909952 |
|---|---|
| author | D.V. Pérez Civantos M. Robles Marcos J.R. Azanza Perea C. Pazos Pacheco F. García-Montoto Pérez V. Jerez Gómez-Coronado |
| author_facet | D.V. Pérez Civantos M. Robles Marcos J.R. Azanza Perea C. Pazos Pacheco F. García-Montoto Pérez V. Jerez Gómez-Coronado |
| author_sort | D.V. Pérez Civantos |
| collection | DOAJ |
| description | Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that therapeutic levels are achieved within the peritoneal cavity. Methods: A descriptive, open, prospective, observational, multicentre and non-interventional study was performed. Anidulafungin was used at conventional doses. Blood and PF samples were obtained on day 2 of treatment or on any of the following days. Results: A total of 31 patients in a serious clinical condition, as demonstrated by high mean clinical severity scale scores (APACHE II and SOFA scores), were included in the study. The mean area under the curve (AUC) in PF was 30% (31 ± 19%) of that determined in the plasma and the maximum concentration (Cmax) reached in PF (mg/l) was close to 1 (0.9 ± 0.5). No adverse effects were observed in any of the 31 patients. Conclusions: Anidulafungin at conventional doses reaches PF concentrations that exceed the minimum inhibitory concentration of the usual Candida spp, which explains the proven efficacy of this echinocandin in the treatment of Candida peritonitis in critically ill patients. Keywords: Anidulafungin, Pharmacokinetics, Peritoneal fluid, Candida peritonitis, Critically ill patients |
| first_indexed | 2024-04-13T02:01:40Z |
| format | Article |
| id | doaj.art-7552281a68a4420392c07dcefbe03a3a |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-13T02:01:40Z |
| publishDate | 2019-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-7552281a68a4420392c07dcefbe03a3a2022-12-22T03:07:36ZengElsevierInternational Journal of Infectious Diseases1201-97122019-09-0186142146Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitisD.V. Pérez Civantos0M. Robles Marcos1J.R. Azanza Perea2C. Pazos Pacheco3F. García-Montoto Pérez4V. Jerez Gómez-Coronado5Department of Intensive and Critical Care Medicine, University Hospital of Badajoz, Badajoz, Spain; Corresponding author at: Intensive and Critical Care Department. University Hospital of Badajoz. Avda Elvas s/n. 06080. Badajoz. Spain.Department of Intensive and Critical Care Medicine, University Hospital of Badajoz, Badajoz, SpainPharmacology Department, Pharmacology and Clinical Central Research, University of Navarra, Pamplona, SpainClinical Microbiology Department, University Hospital San Pedro de Alcántara, Cáceres, SpainAnaesthesia and Perioperative Department, University Hospital San Pedro de Alcántara, Cáceres, SpainDepartment of Intensive and Critical Care Medicine, University Hospital of Badajoz, Badajoz, Spain; Head of the Department of Intensive and Critical Care Medicine, University Hospital of Badajoz, SpainObjective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that therapeutic levels are achieved within the peritoneal cavity. Methods: A descriptive, open, prospective, observational, multicentre and non-interventional study was performed. Anidulafungin was used at conventional doses. Blood and PF samples were obtained on day 2 of treatment or on any of the following days. Results: A total of 31 patients in a serious clinical condition, as demonstrated by high mean clinical severity scale scores (APACHE II and SOFA scores), were included in the study. The mean area under the curve (AUC) in PF was 30% (31 ± 19%) of that determined in the plasma and the maximum concentration (Cmax) reached in PF (mg/l) was close to 1 (0.9 ± 0.5). No adverse effects were observed in any of the 31 patients. Conclusions: Anidulafungin at conventional doses reaches PF concentrations that exceed the minimum inhibitory concentration of the usual Candida spp, which explains the proven efficacy of this echinocandin in the treatment of Candida peritonitis in critically ill patients. Keywords: Anidulafungin, Pharmacokinetics, Peritoneal fluid, Candida peritonitis, Critically ill patientshttp://www.sciencedirect.com/science/article/pii/S1201971219302930 |
| spellingShingle | D.V. Pérez Civantos M. Robles Marcos J.R. Azanza Perea C. Pazos Pacheco F. García-Montoto Pérez V. Jerez Gómez-Coronado Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis International Journal of Infectious Diseases |
| title | Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis |
| title_full | Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis |
| title_fullStr | Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis |
| title_full_unstemmed | Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis |
| title_short | Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis |
| title_sort | pharmacokinetics of anidulafungin in critically ill patients with candida peritonitis |
| url | http://www.sciencedirect.com/science/article/pii/S1201971219302930 |
| work_keys_str_mv | AT dvperezcivantos pharmacokineticsofanidulafunginincriticallyillpatientswithcandidaperitonitis AT mroblesmarcos pharmacokineticsofanidulafunginincriticallyillpatientswithcandidaperitonitis AT jrazanzaperea pharmacokineticsofanidulafunginincriticallyillpatientswithcandidaperitonitis AT cpazospacheco pharmacokineticsofanidulafunginincriticallyillpatientswithcandidaperitonitis AT fgarciamontotoperez pharmacokineticsofanidulafunginincriticallyillpatientswithcandidaperitonitis AT vjerezgomezcoronado pharmacokineticsofanidulafunginincriticallyillpatientswithcandidaperitonitis |